# Beyond Air, Inc.: overview XAIR · Nasdaq · CIK 1641631 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31 Pages: [Overview](/companies/xair.md) · [Financials](/companies/xair/financials.md) · [Filings](/companies/xair/filings.md) · [Insiders](/companies/xair/insiders.md) Latest reported revenue: [$1.8m](/filings/0001493152-26-037781.md) for Q1 FY2027, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-037781). ## Last eight quarters | Line item | Unit | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.8](/filings/0001493152-25-021561.md) | [1.1](/filings/0001493152-26-006688.md) | [1.2 d](/filings/0001493152-26-030287.md) | [1.8](/filings/0001493152-26-037781.md) | [1.8](/filings/0001493152-25-021561.md) | [2.2](/filings/0001493152-26-006688.md) | [1.9 d](/filings/0001493152-26-030287.md) | [1.8](/filings/0001493152-26-037781.md) | | Gross margin | % | [(135.8%)](/filings/0001493152-25-021561.md) | [(20.1%)](/filings/0001493152-26-006688.md) | [(2.8%) d](/filings/0001493152-26-030287.md) | [8.9%](/filings/0001493152-26-037781.md) | [(16.4%)](/filings/0001493152-25-021561.md) | [13.7%](/filings/0001493152-26-006688.md) | [4.9% d](/filings/0001493152-26-030287.md) | [12.7%](/filings/0001493152-26-037781.md) | | Operating margin | % | [(1608.1%)](/filings/0001493152-25-021561.md) | [(1021.6%)](/filings/0001493152-26-006688.md) | [(622.7%) d](/filings/0001493152-26-030287.md) | [(432.8%)](/filings/0001493152-26-037781.md) | [(421.4%)](/filings/0001493152-25-021561.md) | [(300.6%)](/filings/0001493152-26-006688.md) | [(376.0%) d](/filings/0001493152-26-030287.md) | [(374.0%)](/filings/0001493152-26-037781.md) | | Net margin | % | [(1673.9%)](/filings/0001493152-25-021561.md) | [(1215.7%)](/filings/0001493152-26-006688.md) | [(697.4%) d](/filings/0001493152-26-030287.md) | [(437.0%)](/filings/0001493152-26-037781.md) | [(436.7%)](/filings/0001493152-25-021561.md) | [(334.4%)](/filings/0001493152-26-006688.md) | [(539.2%) d](/filings/0001493152-26-030287.md) | [(448.8%)](/filings/0001493152-26-037781.md) | | Diluted EPS | $ per share | [(5.67)](/filings/0001493152-25-021561.md) | [(2.96)](/filings/0001493152-26-006688.md) | not reported | [(30.67)](/filings/0001493152-26-037781.md) | [(1.25)](/filings/0001493152-25-021561.md) | [(0.85)](/filings/0001493152-26-006688.md) | not reported | [(11.00)](/filings/0001493152-26-037781.md) | | Free cash flow | $m | [(14.5) d](/filings/0001493152-25-021561.md) | [(8.3) d](/filings/0001493152-26-006688.md) | [(8.5) d](/filings/0001493152-26-030287.md) | [(4.7)](/filings/0001493152-26-037781.md) | [(4.7) d](/filings/0001493152-25-021561.md) | [(4.3) d](/filings/0001493152-26-006688.md) | [(5.5) d](/filings/0001493152-26-030287.md) | [(5.2)](/filings/0001493152-26-037781.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-03-31) | FY2023 (2023-03-31) | FY2024 (2024-03-31) | FY2025 (2025-03-31) | FY2026 (2026-03-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | [1.2](/filings/0001641172-25-015750.md) | [3.7](/filings/0001493152-26-030287.md) | [7.7](/filings/0001493152-26-030287.md) | | Gross margin | % | not reported | not reported | [(112.8%)](/filings/0001641172-25-015750.md) | [(44.9%)](/filings/0001493152-26-030287.md) | [3.3%](/filings/0001493152-26-030287.md) | | Operating margin | % | not reported | not reported | [(5436.2%)](/filings/0001641172-25-015750.md) | [(1202.1%)](/filings/0001493152-26-030287.md) | [(378.2%)](/filings/0001493152-26-030287.md) | | Net margin | % | not reported | not reported | [(5197.8%)](/filings/0001641172-25-015750.md) | [(1258.4%)](/filings/0001493152-26-030287.md) | [(433.0%)](/filings/0001493152-26-030287.md) | | Diluted EPS | $ per share | not reported | [(1.86)](/filings/0001493152-24-025000.md) | [(1.82)](/filings/0001641172-25-015750.md) | [(13.77)](/filings/0001493152-26-030287.md) | [(4.01)](/filings/0001493152-26-030287.md) | | Free cash flow | $m | [(24.5)](/filings/0001493152-23-022150.md) | [(36.9)](/filings/0001493152-24-025000.md) | [(61.8)](/filings/0001641172-25-015750.md) | [(44.1)](/filings/0001493152-26-030287.md) | [(19.2)](/filings/0001493152-26-030287.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/xair/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $7 | 15 | | New +15 | ## Recent filings [All 630 filings](/companies/xair/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-30 | 16:31 ET | [DEF 14A](/filings/0001493152-26-049442.md) | Proxy statement, period 2026-10-30 | 0001493152-26-049442 | | 2026-10-08 | 08:40 ET | [8-K](/filings/0001493152-26-046268.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-046268 | | 2026-09-24 | 16:30 ET | [8-K](/filings/0001493152-26-044155.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-044155 | | 2026-08-18 | 16:30 ET | [8-K](/filings/0001493152-26-039020.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-039020 | | 2026-08-13 | 16:16 ET | [10-Q](/filings/0001493152-26-037781.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037781 | | 2026-08-06 | 16:37 ET | [8-K](/filings/0001493152-26-036367.md) | 8.01 Other events | 0001493152-26-036367 | | 2026-07-31 | 08:30 ET | [8-K](/filings/0001493152-26-035550.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-035550 | | 2026-07-09 | 09:20 ET | [8-K](/filings/0001493152-26-032621.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001493152-26-032621 | | 2026-06-26 | 16:30 ET | [8-K](/filings/0001493152-26-030305.md) | 2.02 Results of operations; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-030305 | | 2026-06-26 | 16:06 ET | [10-K](/filings/0001493152-26-030287.md) | Annual report, period 2026-03-31 | 0001493152-26-030287 | ## Latest annual report [Form 10-K for the fiscal year ended Mar 31, 2026](/filings/0001493152-26-030287.md), filed Jun 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1641631 - Tickers: XAIR - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 16:45 ET. No prices; not investment advice.